Corient Private Wealth LLC Sells 3,631 Shares of Astrazeneca Plc $AZN

Corient Private Wealth LLC reduced its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 1.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 208,747 shares of the company’s stock after selling 3,631 shares during the quarter. Corient Private Wealth LLC’s holdings in Astrazeneca were worth $36,635,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Brighton Jones LLC increased its holdings in Astrazeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after acquiring an additional 2,789 shares during the period. AQR Capital Management LLC boosted its holdings in Astrazeneca by 45.3% in the 1st quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock valued at $2,756,000 after purchasing an additional 11,690 shares during the period. Amundi boosted its holdings in Astrazeneca by 54.4% in the 2nd quarter. Amundi now owns 10,274 shares of the company’s stock valued at $731,000 after purchasing an additional 3,618 shares during the period. Jump Financial LLC grew its position in shares of Astrazeneca by 898.4% during the 2nd quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock valued at $2,339,000 after purchasing an additional 30,125 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its position in shares of Astrazeneca by 1.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after purchasing an additional 559 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on AZN. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Astrazeneca in a research report on Monday, June 8th. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Astrazeneca presently has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Stock Performance

Astrazeneca stock opened at $174.87 on Monday. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The stock has a market cap of $271.20 billion, a P/E ratio of 26.26, a price-to-earnings-growth ratio of 1.52 and a beta of 0.25. The firm’s fifty day moving average price is $186.62 and its 200-day moving average price is $186.48.

Astrazeneca (NYSE:AZN) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, equities research analysts expect that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.